Figure 4.

In vivo efficacy and NFκB activation in H358 xenografts in response to enavatuzumab. (A) H358 xenograft tumors at ~100 mm³ in ICR SCID mice were treated i.p. with enavatuzumab, enavatuzumab-Fc mutant, or IgG1 control at 10 mg/kg q3w as indicated. (B) H358 xenografts were treated on days 0 and 3 with enavatuzumab or control antibody. Tumors from three mice from each treatment group were excised on day 4, after which cell lysates were prepared and analyzed by Western blot. Activation of NFκB was examined by measuring RelB, p105/p50, p52, and p65 levels in the tumors.